Jazz Pharmaceuticals (JAZZ) Stock Rating Reaffirmed by B. Riley

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “buy” rating reiterated by B. Riley in a research report issued on Tuesday. They presently have a $206.00 price objective on the specialty pharmaceutical company’s stock. B. Riley’s price objective would indicate a potential upside of 51.75% from the stock’s current price.

Several other equities research analysts have also issued reports on the stock. Mizuho increased their target price on shares of Jazz Pharmaceuticals from $144.00 to $150.00 and gave the stock a “neutral” rating in a report on Tuesday. Cantor Fitzgerald reissued a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Sunday. Zacks Investment Research lowered shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, November 10th. HC Wainwright reissued a “neutral” rating and issued a $150.00 target price (up from $144.00) on shares of Jazz Pharmaceuticals in a report on Friday, November 10th. Finally, UBS reduced their target price on shares of Jazz Pharmaceuticals from $172.00 to $168.00 and set a “buy” rating for the company in a report on Wednesday, November 8th. Two analysts have rated the stock with a sell rating, five have given a hold rating and nineteen have assigned a buy rating to the company’s stock. Jazz Pharmaceuticals has a consensus rating of “Buy” and an average target price of $181.28.

Jazz Pharmaceuticals (JAZZ) traded down $0.81 during trading on Tuesday, reaching $135.75. 451,300 shares of the company traded hands, compared to its average volume of 508,983. The stock has a market cap of $8,186.84, a price-to-earnings ratio of 17.13, a price-to-earnings-growth ratio of 0.88 and a beta of 0.98. Jazz Pharmaceuticals has a one year low of $99.28 and a one year high of $163.75. The company has a quick ratio of 2.94, a current ratio of 3.10 and a debt-to-equity ratio of 0.63.

In other news, SVP Iain Mcgill sold 8,000 shares of the stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $133.42, for a total transaction of $1,067,360.00. Following the completion of the transaction, the senior vice president now directly owns 28,383 shares in the company, valued at approximately $3,786,859.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Patrick G. Enright sold 352 shares of the stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $133.19, for a total value of $46,882.88. Following the transaction, the director now owns 1,365 shares of the company’s stock, valued at $181,804.35. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,352 shares of company stock valued at $1,417,763. Insiders own 4.30% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its position in shares of Jazz Pharmaceuticals by 49.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 229,898 shares of the specialty pharmaceutical company’s stock valued at $35,750,000 after acquiring an additional 75,703 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Jazz Pharmaceuticals by 41.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock valued at $218,540,000 after acquiring an additional 410,031 shares during the last quarter. Summit Partners Public Asset Management LLC bought a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at approximately $10,108,000. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its position in shares of Jazz Pharmaceuticals by 13.8% during the 2nd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 17,469 shares of the specialty pharmaceutical company’s stock valued at $2,716,000 after acquiring an additional 2,121 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its position in shares of Jazz Pharmaceuticals by 11,990.7% during the 2nd quarter. Janus Henderson Group PLC now owns 873,919 shares of the specialty pharmaceutical company’s stock valued at $135,894,000 after acquiring an additional 866,691 shares during the last quarter. Hedge funds and other institutional investors own 91.30% of the company’s stock.

WARNING: “Jazz Pharmaceuticals (JAZZ) Stock Rating Reaffirmed by B. Riley” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://ledgergazette.com/2017/12/06/jazz-pharmaceuticals-jazz-stock-rating-reaffirmed-by-b-riley.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply